KM Research Hub
← 返回论文库
待处理 入排:排除 图源:待检查 入排置信度 0.98

Dupilumab treatment improves signs, symptoms, quality of life, and work productivity in patients with atopic hand and foot dermatitis: Results from a phase 3, randomized, double-blind, placebo-controlled trial.

Eric L Simpson, Jonathan I Silverberg, Margitta Worm, Golara Honari, Koji Masuda, Ewa Syguła, Marie L A Schuttelaar, Eric Mortensen, Elizabeth Laws, Bolanle Akinlade, Naimish Patel, Jennifer Maloney, Heather Paleczny, Dimittri Delevry, Jing Xiao, Ariane Dubost-Brama, Ashish Bansal

J Am Acad Dermatol 90(6) 1190-1199

PMID38296199
PMCID-
DOI10.1016/j.jaad.2023.12.066
发表日期2024-01-31
入排依据:未发现恶性肿瘤人群证据。
摘要

摘要

BACKGROUND: Despite high disease burden, systemic treatment options for patients with atopic hand and/or foot dermatitis (H/F AD) are limited. OBJECTIVES: To evaluate efficacy and safety of dupilumab in H/F AD using specific instruments for assessing disease severity on hands and feet. METHODS: In this multicenter phase 3 trial, adults and adolescents with moderate-to-severe H/F AD were randomized to dupilumab monotherapy (regimen approved for generalized AD), or matched placebo. The primary endpoint was proportion of patients achieving Hand and Foot Investigator's Global Assessment score 0 or 1 at week 16. Secondary prespecified endpoints assessed the severity and extent of signs, symptom intensity (itch, pain), quality of life, and sleep. RESULTS: A total of 133 patients (adults = 106, adolescents = 27) were randomized to dupilumab (n = 67) or placebo (n = 66). At week 16, significantly more patients receiving dupilumab (n = 27) than placebo (n = 11) achieved Hand and Foot Investigator's Global Assessment score 0 or 1 (40.3% vs 16.7%; P = .003). All other prespecified endpoints were met. Safety was consistent with the known AD dupilumab profile. LIMITATIONS: Short-term, 16-week treatment period. CONCLUSION: Dupilumab monotherapy resulted in significant improvements across different domains of H/F AD with acceptable safety, supporting dupilumab as a systemic treatment approach for this often difficult to treat condition.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。